A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group
- PMID: 1734247
- DOI: 10.1056/NEJM199202273260901
A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group
Abstract
Background and methods: The use of corticosteroids to treat optic neuritis is controversial. At 15 clinical centers, we randomly assigned 457 patients with acute optic neuritis to receive oral prednisone (1 mg per kilogram of body weight per day) for 14 days; intravenous methylprednisolone (1 g per day) for 3 days, followed by oral prednisone (1 mg per kilogram per day) for 11 days; or oral placebo for 14 days. Visual function was assessed over a six-month follow-up period.
Results: Visual function recovered faster in the group receiving intravenous methylprednisolone than in the placebo group; this was particularly true for the reversal of visual-field defects (P = 0.0001). Although the differences between the groups decreased with time, at six months the group that received intravenous methylprednisolone still had slightly better visual fields (P = 0.054), contrast sensitivity (P = 0.026), and color vision (P = 0.033) but not better visual acuity (P = 0.66). The outcome in the oral-prednisone group did not differ from that in the placebo group. In addition, the rate of new episodes of optic neuritis in either eye was higher in the group receiving oral prednisone, but not the group receiving intravenous methylprednisolone, than in the placebo group (relative risk for oral prednisone vs. placebo, 1.79; 95 percent confidence interval, 1.08 to 2.95).
Conclusions: Intravenous methylprednisolone followed by oral prednisone speeds the recovery of visual loss due to optic neuritis and results in slightly better vision at six months. Oral prednisone alone, as prescribed in this study, is an ineffective treatment and increases the risk of new episodes of optic neuritis.
Comment in
-
Corticosteroid treatment of acute optic neuritis.N Engl J Med. 1992 Feb 27;326(9):634-5. doi: 10.1056/NEJM199202273260909. N Engl J Med. 1992. PMID: 1734254 Clinical Trial. No abstract available.
Similar articles
-
The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group.N Engl J Med. 1993 Dec 9;329(24):1764-9. doi: 10.1056/NEJM199312093292403. N Engl J Med. 1993. PMID: 8232485 Clinical Trial.
-
[Comparative treatment of acute optic neuritis with "boluses" of intravenous methylprednisolone or oral prednisone].Gac Med Mex. 1994 Jul-Aug;130(4):227-30. Gac Med Mex. 1994. PMID: 8964329 Clinical Trial. Spanish.
-
[Short-term effect of megadose steroid therapy in optic neuritis].Klin Monbl Augenheilkd. 1992 Dec;201(6):375-80. doi: 10.1055/s-2008-1045915. Klin Monbl Augenheilkd. 1992. PMID: 1287359 German.
-
Corticosteroids for treating optic neuritis.Cochrane Database Syst Rev. 2015 Aug 14;2015(8):CD001430. doi: 10.1002/14651858.CD001430.pub4. Cochrane Database Syst Rev. 2015. PMID: 26273799 Free PMC article. Review.
-
[What is new in neuro-ophthalmology? Diagnosis, therapy and patient education in optic nerve neuritis].Klin Monbl Augenheilkd. 1993 Sep;203(3):159-66. doi: 10.1055/s-2008-1045662. Klin Monbl Augenheilkd. 1993. PMID: 8264205 Review. German.
Cited by
-
Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis.Front Immunol. 2024 Jun 13;15:1404316. doi: 10.3389/fimmu.2024.1404316. eCollection 2024. Front Immunol. 2024. PMID: 38938576 Free PMC article.
-
Elevated Neutrophil Lymphocyte Ratio in Recurrent Optic Neuritis.J Ophthalmol. 2015;2015:758687. doi: 10.1155/2015/758687. Epub 2015 Apr 28. J Ophthalmol. 2015. PMID: 26060578 Free PMC article.
-
Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives.Neurology. 2024 Aug 13;103(3):e209677. doi: 10.1212/WNL.0000000000209677. Epub 2024 Jul 17. Neurology. 2024. PMID: 39018513 Review.
-
Therapeutic management of severe relapses in multiple sclerosis.Curr Treat Options Neurol. 2015 Apr;17(4):345. doi: 10.1007/s11940-015-0345-6. Curr Treat Options Neurol. 2015. PMID: 25794777
-
IL-17A expression by both T cells and non-T cells contribute to HSV-IL-2-induced CNS demyelination.Front Immunol. 2023 Feb 2;14:1102486. doi: 10.3389/fimmu.2023.1102486. eCollection 2023. Front Immunol. 2023. PMID: 36817487 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources